MedPath

Multicenter comparative study to examine the efficacy of zoledronic acid in prostate cancer with bone metastasis at different hormone sensitivity status.

Not Applicable
Recruiting
Conditions
Prostate cancer with bone metastasis
Registration Number
JPRN-UMIN000002792
Lead Sponsor
Tama Prostate cancer Bone metastasis Study group
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Male
Target Recruitment
200
Inclusion Criteria

Not provided

Exclusion Criteria

1.History of hypersensitivity for zoledronic acid or other bisphosphonate 2.Renal dysfunction(serum creatinine more than 3.0mg/dL) 3.Active concomititant malignancy 4.Severe coexisting disease 5.Invasive dental treatment within 3 months 6.Other bisphosphonate therapy for injection within 6 months 7.Not suitable for this trial

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath